Back to top
more

Iovance Biotherapeutics (IOVA)

(Delayed Data from NSDQ)

$11.87 USD

11.87
8,980,181

+0.25 (2.15%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $11.82 -0.05 (-0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Dec 28, 2023

by Zacks Equity Research

Companies In The Article Are:CYTK,TSLA, NYT, MSFT, IOVA

Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates

by Zacks Equity Research

Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

by Zacks Equity Research

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug

by Zacks Equity Research

Iovance (IOVA) rises despite the FDA's postponement of the decision date regarding the regulatory filing for its lead candidate, lifileucel, to treat advanced melanoma due to resource constraints.

Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2

by Zacks Equity Research

Iovance (IOVA) reports mixed second-quarter results as earnings beat estimates but sales miss the mark.

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 41.98% and 96.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug

by Zacks Equity Research

Based on feedback from the FDA, Iovance's (IOVA) ongoing mid-stage study on LN-145 in NSCLC could support approval under the accelerated pathway. IOVA also reports encouraging preliminary data.

Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study

by Zacks Equity Research

Iovance (IOVA) announces randomizing the first patient in the TILVANCE-301 study evaluating the safety and efficacy of its lifileucel/Keytruda combo therapy in frontline advanced melanoma patients.

Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.

FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug

by Zacks Equity Research

The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.

Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.

Why Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug

by Zacks Equity Research

Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.

Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil

by Zacks Equity Research

Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.

Kinjel Shah headshot

Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More

by Kinjel Shah

Let us look at four drug and biotech companies, NVAX, IOVA, ALLO, SRPT and FATE, which are gearing up for their earnings release.

Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%

by Zacks Equity Research

Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.

Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug

by Zacks Equity Research

Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.

Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study

by Zacks Equity Research

Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.

Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy

by Zacks Equity Research

Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy

by Zacks Equity Research

Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.